Cash/Burn From SEC Filing For Period: 

Q1 '20

NVAX

Novavax

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.

Cash

$237.4M

Burn Rate

-$25.9M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

NanoFlu vaccine

Influenza

BLA: Preparing Submission

TBA

RSV Vaccine

RSV - Infants Via Maternal Immunization

Phase 3 Topline Data/ FDA Recommends Additional Studies

TBD

RSV Vaccine

RSV - Older Adults

Phase 2

NVX-CoV2373

COVID-19 Vaccine

Phase 1 (Preliminary Safety & Immunogenicity Data)

July 2020

RSV Vaccine

RSV - Pediatrics

Phase 1

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon